A Phase 3 interventional study of Botulinum Toxin Type A and Placebo in Masseter Muscle Prominence, sponsored by AbbVie. Completed at 21 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-06.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is designed to evaluate the safety and effectiveness of administering BOTOX for the treatment of Masseter Muscle Prominence (MMP) in adults.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Botulinum Toxin Type A (BOTOX ®) will be administered on Day 1 as bilateral intramuscular injections into the masseter with the possibility of 2 additional treatments
Biological: Botulinum Toxin Type A
Placebo (normal saline) will be administered on Day 1 as bilateral intramuscular injections into the masseter
Other: Placebo
Day 1 Administration of bilateral intramuscular injections into the masseter
Also known as: OnabotulinumtoxinA, BOTOX®
Day 1 Administration of bilateral intramuscular injections of placebo (normal saline) into the masseter
Achievement of ≥ 2-Grade Improvement From Baseline on the Masseter Muscle Prominence Scale (MMPS) at Day 90
Proportion of participants who achieve ≥ 2-grade improvement from baseline at Day 90, per investigator assessments of MMP using the Masseter Muscle Prominence Scale (MMPS). MMPS ranges from 1 = minimal to 5 = very marked.
Time frame: Day 90
Achievement of MMPS Grade ≤ 3 at Day 90
Proportion of participants who achieve MMPS Grade of ≤ 3 at Day 90, per investigator assessments of MMP using the Masseter Muscle Prominence Scale (MMPS). MMPS ranges from 1 = minimal to 5 = very marked.
Time frame: Day 90
Achievement of MMPS-P Grade ≤ 3 on Day 90
Proportion of participants who achieve MMPS-P Grade ≤ 3 at Day 90, according to participant, per Masseter Muscle Prominence Scale-Participant (MMPS-P) MMPS-P ranges from 1 = not at all pronounced to 5 = very pronounced.
Time frame: Day 90
Achievement of MMPS-P ≥ 2-Grade Improvement From Baseline at Day 90
Proportion of participants who achieve ≥ 2-grade improvement from baseline at Day 90, per Masseter Muscle Prominence Scale-Participant (MMPS-P) MMPS-P ranges from 1 = not at all pronounced to 5 = very pronounced.
Time frame: Day 90
Achievement of PSAC Grade ≥ 1 (at Least Minimally Improved From Baseline) on Day 90
Proportion of participants who achieve Grade ≥ 1 on Participant Self-Assessment of Change (PSAC) (at least minimally improved from baseline) at Day 90 PSAC ranges from 3 = much improved to -3 = much worse.
Time frame: Day 90
Change From Baseline in Lower Facial Width (mm) at Day 90
Calculated from standardized images, measured in millimeters (mm)
Time frame: Day 90
Median Duration of Effect for MMPS Responders
Median duration of effect for BOTOX-treated MMPS responders.
Time frame: Up to Day 360
A total of 377 participants were enrolled and randomized into the study; 284 to BOTOX and 93 to Placebo. A total of 370 participants were included in the modified ITT (mITT) Population; 278 to BOTOX and 92 to Placebo. A participant was considered to have completed the study if he/she had at least completed the treatment visit and the end of study visit.
| Milestone | Placebo | BOTOX® |
|---|---|---|
| Started | 93 | 284 |
| Mitt population | 92 | 278 |
| Completed | 70 | 240 |
| Not completed | 23 | 44 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Withdrawal by subject | 16 | 36 |
| Withdrew: Lost to follow-up | 6 | 1 |
| Withdrew: Protocol deviation | 0 | 4 |
| Withdrew: Other | 1 | 1 |
Proportion of participants who achieve ≥ 2-grade improvement from baseline at Day 90, per investigator assessments of MMP using the Masseter Muscle Prominence Scale (MMPS). MMPS ranges from 1 = minimal to 5 = very marked.
| percentage of participants | Placebo | BOTOX® |
|---|---|---|
| Achievement of ≥ 2-Grade Improvement From Baseline on the Masseter Muscle Prominence Scale (MMPS) at Day 90 | 2.2 (0.0 to 5.2) | 51.2 (45.2 to 57.2) |
Proportion of participants who achieve MMPS Grade of ≤ 3 at Day 90, per investigator assessments of MMP using the Masseter Muscle Prominence Scale (MMPS). MMPS ranges from 1 = minimal to 5 = very marked.
| percentage of participants | Placebo | BOTOX® |
|---|---|---|
| Achievement of MMPS Grade ≤ 3 at Day 90 | 9.9 (3.8 to 16.1) | 81.1 (76.4 to 85.9) |
Proportion of participants who achieve MMPS-P Grade ≤ 3 at Day 90, according to participant, per Masseter Muscle Prominence Scale-Participant (MMPS-P) MMPS-P ranges from 1 = not at all pronounced to 5 = very pronounced.
| percentage of participants | Placebo | BOTOX® |
|---|---|---|
| Achievement of MMPS-P Grade ≤ 3 on Day 90 | 19.5 (11.2 to 27.8) | 76.2 (71.1 to 81.4) |
Proportion of participants who achieve ≥ 2-grade improvement from baseline at Day 90, per Masseter Muscle Prominence Scale-Participant (MMPS-P) MMPS-P ranges from 1 = not at all pronounced to 5 = very pronounced.
| percentage of participants | Placebo | BOTOX® |
|---|---|---|
| Achievement of MMPS-P ≥ 2-Grade Improvement From Baseline at Day 90 | 9.1 (3.1 to 15.0) | 58.8 (52.9 to 64.7) |
Proportion of participants who achieve Grade ≥ 1 on Participant Self-Assessment of Change (PSAC) (at least minimally improved from baseline) at Day 90 PSAC ranges from 3 = much improved to -3 = much worse.
| percentage of participants | Placebo | BOTOX® |
|---|---|---|
| Achievement of PSAC Grade ≥ 1 (at Least Minimally Improved From Baseline) on Day 90 | 20.4 (12.0 to 28.7) | 90.8 (87.3 to 94.4) |
Calculated from standardized images, measured in millimeters (mm)
| millimeters (mm) | Placebo | BOTOX® |
|---|---|---|
| Change From Baseline in Lower Facial Width (mm) at Day 90 | -0.04 ± 0.202 | -5.24 ± 0.121 |
Median duration of effect for BOTOX-treated MMPS responders.
| Days | BOTOX® |
|---|---|
| MMPS ≥ 2-Grade Improvement | 176.0 (154.0 to 183.0) |
| MMPS Grade ≤ 3 | 213.0 (204.0 to 236.0) |
| MMPS ≥ 1-Grade Improvement | 268.0 (239.0 to 304.0) |
Collected over All-cause mortality and adverse event tables include events reported from the start of safety data collection/time of informed consent/enrollment (whichever study team prefers per protocol/study design) to the end of the study. The median time on follow-up (or mean time followed) was 539.0 and 540.0 Days for Placebo and BOTOX ®, respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/93 (0%) | 4/93 (4.3%) | 19/93 (20.4%) |
| BOTOX® | 0/283 (0%) | 11/283 (3.9%) | 54/283 (19.1%) |
| Event | Placebo | BOTOX® |
|---|---|---|
| POST HERPETIC NEURALGIANervous system disorders | 1/93 | 0/283 |
| ENDOMETRIOSISReproductive system and breast disorders | 1/93 | 0/283 |
| NASAL SEPTUM DEVIATIONRespiratory, thoracic and mediastinal disorders | 1/93 | 0/283 |
| ABORTION INDUCEDSurgical and medical procedures | 1/93 | 3/283 |
| VENTRICULAR EXTRASYSTOLESCardiac disorders | 0/93 | 1/283 |
| HAEMORRHOIDSGastrointestinal disorders | 0/93 | 1/283 |
| GALLBLADDER POLYPHepatobiliary disorders | 0/93 | 1/283 |
| POST-ACUTE COVID-19 SYNDROMEInfections and infestations | 0/93 | 1/283 |
| PULMONARY TUBERCULOSISInfections and infestations | 0/93 | 1/283 |
| ABORTION OF ECTOPIC PREGNANCYPregnancy, puerperium and perinatal conditions | 0/93 | 1/283 |
| Event | Placebo | BOTOX® |
|---|---|---|
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 6/93 | 18/283 |
| MASTICATION DISORDERMusculoskeletal and connective tissue disorders | 6/93 | 14/283 |
| HEADACHENervous system disorders | 6/93 | 11/283 |
| NASOPHARYNGITISInfections and infestations | 3/93 | 17/283 |
Modified Intent-to-Treat (mITT) Population
| Age, Continuous(years) | Placebo | BOTOX® | Total |
|---|---|---|---|
| Mean | 31.0 ± 8.67 | 31.5 ± 8.35 | 31.4 ± 8.42 |
| Sex: Female, Male(Participants) | Placebo | BOTOX® | Total |
|---|---|---|---|
| Female | 82 | 244 | 326 |
| Male | 10 | 34 | 44 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | BOTOX® | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 4 | 5 |
| Not Hispanic or Latino | 91 | 274 | 365 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | BOTOX® | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 76 | 247 | 323 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 1 | 0 | 1 |
| White | 15 | 29 | 44 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Baseline Masseter Muscle Prominence Scale (MMPS)(Participants) | Placebo | BOTOX® | Total |
|---|---|---|---|
| 4 = Marked | 59 | 177 | 236 |
| 5 = Very Marked | 33 | 101 | 134 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Aug 2019 to primary completion in Nov 2022, 38 months.
Results were first posted in May 2025, 2 years 5 months after primary completion. A results delay was requested in Oct 2023.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A